Log in

NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, Forecast & News

$1.22
-0.02 (-1.61 %)
(As of 12/16/2019 09:07 AM ET)
Today's Range
$1.17
Now: $1.22
$1.29
50-Day Range
$0.72
MA: $0.97
$1.25
52-Week Range
$0.71
Now: $1.22
$6.31
Volume230,769 shs
Average Volume391,401 shs
Market Capitalization$127.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADAP
CUSIPN/A
Phone44-12-3543-0000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.51 million
Book Value$2.36 per share

Profitability

Net Income$-95,510,000.00

Miscellaneous

Employees406
Market Cap$127.72 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive ADAP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.


Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) released its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.03. The biotechnology company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $7 million. View Adaptimmune Therapeutics' Earnings History.

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Adaptimmune Therapeutics.

What price target have analysts set for ADAP?

7 equities research analysts have issued twelve-month target prices for Adaptimmune Therapeutics' shares. Their forecasts range from $4.15 to $8.00. On average, they anticipate Adaptimmune Therapeutics' share price to reach $6.03 in the next year. This suggests a possible upside of 394.3% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

What is the consensus analysts' recommendation for Adaptimmune Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

Has Adaptimmune Therapeutics been receiving favorable news coverage?

News coverage about ADAP stock has been trending somewhat negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adaptimmune Therapeutics earned a news impact score of -1.7 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Adaptimmune Therapeutics.

Are investors shorting Adaptimmune Therapeutics?

Adaptimmune Therapeutics saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 2,920,000 shares, an increase of 11.5% from the November 14th total of 2,620,000 shares. Based on an average trading volume of 347,900 shares, the short-interest ratio is currently 8.4 days. Currently, 3.3% of the company's shares are short sold. View Adaptimmune Therapeutics' Current Options Chain.

Who are some of Adaptimmune Therapeutics' key competitors?

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Chipotle Mexican Grill (CMG) and Micron Technology (MU).

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the folowing people:
  • Mr. James Julian Noble, CEO & Director (Age 60)
  • Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 52)
  • Mr. Adrian Rawcliffe, Chief Financial Officer (Age 47)
  • Mr. William C. Bertrand Jr., Chief Operating Officer (Age 54)
  • Dr. Rafael Amado, Pres of R&D (Age 55)

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Man Group plc (1.96%), Millennium Management LLC (0.87%) and Tower Research Capital LLC TRC (0.02%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, David M Mott, Enterprise Associates 14 New, Gwendolyn Knowlt Binder-Scholl, Lawrence M Alleva, Orbimed Advisors Llc, Peter A Thompson, Rafael Amado, Ravi Viswanathan and William C Bertrand, Jr. View Institutional Ownership Trends for Adaptimmune Therapeutics.

Which institutional investors are buying Adaptimmune Therapeutics stock?

ADAP stock was bought by a variety of institutional investors in the last quarter, including Man Group plc, Millennium Management LLC and Tower Research Capital LLC TRC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, David M Mott, Enterprise Associates 14 New, Lawrence M Alleva and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $1.22.

How big of a company is Adaptimmune Therapeutics?

Adaptimmune Therapeutics has a market capitalization of $127.72 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.View Additional Information About Adaptimmune Therapeutics.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com/.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]


MarketBeat Community Rating for Adaptimmune Therapeutics (NASDAQ ADAP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  522
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote "Outperform" if you believe ADAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Featured Article: What is the CAC 40 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel